Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Net Cash Flow: 2012-2025

Historic Net Cash Flow for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to -$109.9 million.

  • CorMedix's Net Cash Flow fell 1729.66% to -$109.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 153.55%. This contributed to the annual value of -$3.1 million for FY2024, which is 787.85% down from last year.
  • Per CorMedix's latest filing, its Net Cash Flow stood at -$109.9 million for Q3 2025, which was down 218.18% from $93.0 million recorded in Q2 2025.
  • CorMedix's Net Cash Flow's 5-year high stood at $93.0 million during Q2 2025, with a 5-year trough of -$109.9 million in Q3 2025.
  • Moreover, its 3-year median value for Net Cash Flow was -$674,306 (2024), whereas its average is -$1.5 million.
  • Over the last 5 years, CorMedix's Net Cash Flow had its largest YoY gain of 1,485.34% in 2025, and its largest YoY loss of 1,729.66% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Net Cash Flow stood at -$13.0 million in 2021, then skyrocketed by 99.15% to -$111,121 in 2022, then plummeted by 125.54% to -$17.9 million in 2023, then soared by 52.67% to $5.4 million in 2024, then crashed by 1,729.66% to -$109.9 million in 2025.
  • Its Net Cash Flow was -$109.9 million in Q3 2025, compared to $93.0 million in Q2 2025 and $25.6 million in Q1 2025.